Working hand-in-hand with leaders in the pharmaceutical space, we created one of the most scalable and accurate decision-making tools in the world. Our proprietary and innovative SaaS platform, SUM®, strives to improve the speed and value of strategic decisions by basing decisions on data from holistic and dynamic end-to-end models of opportunities and portfolios. The models include any and all uncertainties allowing exploitation of potential upsides and mitigation of risks.
Captario SUM® combines AI and machine learning with multi-dimensional Monte Carlo simulation, enabling unparalleled control, insight, and simulation capabilities for your project or portfolio analysis.
We are proud to support a third of the Top 30 Global Pharma organizations.
We are the change.
Learn more about the evolution of pharma decision-making at www.captario.com
3 articles about Captario
Captario Partners with Sobi to Assist Them with Strategic Drug Development Initiatives
Captario is pleased to announce that Sobi®, one of the largest Swedish biopharmaceutical companies developing and providing sustainable access to innovative medicines for the treatment of rare diseases, has stepped ahead of their peers’ digital journey by choosing to partner with Captario in their efforts to increase efficiency in their strategic drug development initiatives.
Captario Launches Professional Services to Further Enable Strategic Decision-Making
Captario, the life science SaaS-platform decision analytics company, announces the launch of Professional Services to further enable strategic decision-making throughout the drug development process.
Captario Has Been Selected by Alnylam Pharmaceuticals To Optimize Their Portfolio Management Process
Captario, a Gothenburg-based life sciences decision analytics SaaS platform & services company, has been chosen by Alnylam Pharmaceuticals, a global biopharmaceutical company based in Cambridge, MA, to support their digital transformation journey of optimizing strategic project and portfolio forecasting and modeling. Focused on the discovery,